不同经验水平放射科医师间PI-RADS第2版的观察者间一致性与阳性率
回顾性研究纳入160个病灶,由8名不同经验放射科医师按PI-RADS v2评分,以融合靶向活检为参考标准。总体一致性系数0.71,移行带仅0.44;外周带PI-RADS 3+1与4的肿瘤阳性率分别为54.3%和66.0%,移行带分别为25.0%和49.2%(均p<0.001)。
要点
- PI-RADS v2总体观察者间一致性良好(系数0.71),但移行带一致性仅0.44。
- 外周带PI-RADS 3+1阳性率54.3%低于4类66.0%,移行带25.0%低于49.2%。
- 移行带10-14mm与≥15mm病灶阳性率相近(56.5% vs 59.6%,p=0.632)。
核心结论
- PI-RADS v2在不同经验放射科医师间总体观察者间一致性良好;PI-RADS 3+1类显著癌阳性率低于4类;移行带10-14mm病灶阳性率与≥15mm相似。
研究设计与样本
- 经机构审查委员会和伦理委员会批准的回顾性研究,8名不同前列腺MRI经验放射科医师(2名经验丰富、4名中等经验、2名腹部影像研究员)解读160个病灶,以融合靶向活检为参考标准。
诊断标准与关键数值
- 按PI-RADS v2分类的总体一致性系数0.71,外周带0.72,移行带0.44。
- PI-RADS≥3分的一致性:外周带0.48,移行带0.57。
- 外周带肿瘤阳性率:PI-RADS 3+1为54.3%,PI-RADS 4为66.0%(p<0.001)。
- 移行带肿瘤阳性率:PI-RADS 3+1为25.0%,PI-RADS 4为49.2%(p<0.001)。
- MRI使用PI-RADS v2诊断前列腺癌的敏感度、特异度、准确度:外周带76%、72%、74%;移行带76%、69%、71%。
临床应用与阅片要点
- 移行带PI-RADS评分观察者间一致性较低(系数0.44),阅片时需注意。
- 外周带病灶按PI-RADS 3+1与4分类报告,两者显著癌阳性率分别为54.3%和66.0%。
- 移行带病灶按PI-RADS 3+1与4分类报告,阳性率分别为25.0%和49.2%。
- 移行带10-14mm与≥15mm病灶阳性率相近(56.5% vs 59.6%),外周带则随尺寸增大阳性率升高(55.3%、74.6%、93.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To evaluate interobserver agreement of Prostate Imaging Reporting and Data System (PI-RADS) v2 category among radiologists with different levels of experience. The secondary objective was to evaluate the positivity for significant cancer among each category (splitting category 4 into two) and among different lesion sizes.
MATERIALS AND METHODS: Institutional review board and ethics comitee approved retrospective study. Eight radiologists with different levels of experienced in prostatic magnetic resonance imaging-two more experienced, four with intermediate experience, and two abdominal radiology fellows-interpreted 160 lesions. Reference standard was fusion-targeted biopsy. Percentage agreement, k coefficients, and analysis concordance were used.
RESULTS: Coefficient of concordance according to categories was 0.71 considering both zones, 0.72 for peripheral zone (PZ) and 0.44 for peripheral zone (TZ). Agreement for PI-RADS score of 3 or greater was 0.48 in PZ and 0.57 in TZ. Tumor positivity rates were 54.3% and 66.0% for PI-RADS 3 + 1 and 4 for PZ, respectively; and 25.0 and 49.2% for PI-RADS 3 + 1 and 4 for TZ, respectively (p < 0.001 in both analysis). Lesions <10, 10-14, and ≥15 mm had 55.3%, 74.6%, and 93.5% of positivity rates for cancer in PZ (p = 0.002 and <0.001) and 26.7%, 56.5%, and 59.6% in TZ, respectively (p = 0.245 and 0.632). Sensitivities, specificities, and accuracies of magnetic resonance imaging for prostate cancer using PI-RADS v2 were 76%, 72%, and 74% for PZ; and 76%, 69%, and 71% for TZ, respectively.
CONCLUSION: This study shows that PI-RADS v2 has overall good interobserver agreement among radiologists with different levels of experience. PI-RADS category 3 + 1 showed lower positivity rates for significant cancer compared to category 4. Lastly, lesions 10-14 mm has similar positivity rates compared to ≥15 mm for TZ lesions.
引用
- Mussi TC, Yamauchi FI, Tridente CF, et al. Interobserver Agreement and Positivity of PI-RADS Version 2 Among Radiologists with Different Levels of Experience. Acad Radiol. 2018. PMID: 30268722. doi:10.1016/j.acra.2018.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。